Product Details

Ondansetron

Ondansetron Hydrochloride
8 mg
Tablet


DIN/PIN/NPN

02541432

Manufacturer

Sivem Pharmaceuticals ULC

Formulary Listing Date

2024-05-31  

Unit Price

5.1110

Amount MOH Pays

3.8840

Coverage Status

Limited Use Product

ODB Formulary Therapeutic Classification

Therapeutic Note

NO

ATC Code

A04AA01

Interchangeable Products

DIN/ PIN/ NPN Brand name Unit Price Amount MOH pays
02213575 Zofran 23.6170 3.8840
02376105 Septa-Ondansetron 5.1110 3.8840
02274329 Sandoz Ondansetron 5.1110 3.8840
02312255 Ran-Ondansetron 5.1110 3.8840
02258196 PMS-Ondansetron 5.1110 3.8840
02421410 Ondansetron 4.9930 3.8840
02417847 Nat-Ondansetron 5.1110 3.8840
02297876 Mylan-Ondansetron 5.1110 3.8840
02305267 Mint-Ondansetron 5.1110 3.8840
02371758 Mar-Ondansetron 5.1110 3.8840
02313693 Jamp-Ondansetron 5.1110 3.8840
02458802 CCP-Ondansetron 5.1110 3.8840
02288192 Apo-Ondansetron 5.1110 3.8840
02296357 Teva-Ondansetron 5.1110 3.8840
02478935 Accel-Ondansetron 3.8840 3.8840
02541432 Ondansetron 5.1110 3.8840
 

LU Clinical Criteria

LU Code Auth. Period Clinical Criteria
215 1 year

For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy

216 1 year

For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics

217 1 year

For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics

218 1 year

For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation.

454 1 year

For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens

 

EAP Criteria

NO

Product Monograph

View Monograph